Colonisation endpoints in Streptococcus pneumoniae vaccine trials

Kari Auranen, Hanna Rinta-Kokko, David Goldblatt, Hanna Nohynek, Katherine L. O'Brien, Catherine Satzke, Birgit Simell, Antti Tanskanen, Helena Käyhty

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


Evaluating vaccine efficacy for protection against colonisation (VEcol) with bacterial pathogens is an area of growing interest. In this article, we consider estimation of VEcol for colonisation with Streptococcus pneumoniae (the pneumococcus). Colonisation is a common, recurrent and multi-type endpoint that requires both careful definition of the vaccine efficacy parameter and the corresponding method of estimation. We review recent developments in the area and provide practical guidelines for choosing the estimand and the estimation method in trials with a colonisation endpoint. We concentrate on methods that are based on a cross-sectional study design, in which only one nasopharyngeal sample is obtained per study subject.

Original languageEnglish (US)
Pages (from-to)153-158
Number of pages6
Issue number1
StatePublished - Dec 17 2013


  • Nasopharyngeal colonisation
  • Pneumococcus
  • Trial endpoint
  • Vaccine efficacy

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Colonisation endpoints in Streptococcus pneumoniae vaccine trials'. Together they form a unique fingerprint.

Cite this